CN113024516A - 双靶点parp/ezh2抑制剂、制备方法及用途 - Google Patents
双靶点parp/ezh2抑制剂、制备方法及用途 Download PDFInfo
- Publication number
- CN113024516A CN113024516A CN202110337356.4A CN202110337356A CN113024516A CN 113024516 A CN113024516 A CN 113024516A CN 202110337356 A CN202110337356 A CN 202110337356A CN 113024516 A CN113024516 A CN 113024516A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- action
- under
- ezh2 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐,本发明的抑制剂对人乳腺癌细胞MDA‑MB‑231和MDA‑MB‑468和MCF‑7抑制效果较好,对人正常乳腺细胞MCF‑10A和人正常肝细胞L02毒性较小,并且保持了良好的对PARP‑1和EZH2的体外抑制活性,有作为抗肿瘤药物的巨大潜力。
Description
技术领域
本发明涉及化工医药,特别涉及双靶点PARP/EZH2抑制剂、制备方法及用途。
背景技术
乳腺癌是世界上最常见的癌症之一,也是最常见的疾病。三阴性乳腺癌(TNBC),雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2蛋白(HER-2)检测均为阴性,占所有乳腺癌的12-20%。目前对TNBC的治疗选择仅限于高毒性和无法治愈的化疗方案。开发有潜力的治疗TNBC的靶向药物对药物化学家来说仍然是一个巨大的挑战。最大的临床突破出现在PARP抑制剂(PARPi)的发现。该类抑制剂已经被批准用于治疗BRCA1/2突变的肿瘤,具有显著的临床效益。但是80%的TNBC患者没有BRCA突变,这些患者只能选择化疗。扩大PARPi的临床应用用于治疗BRCA精通的TNBC具有很重大的意义。
发明内容
发明目的:本发明目的是提供具有优异的抑制作用的双靶点PARP/EZH2抑制剂、制备方法和用途。
技术方案:本发明提供的如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐,
其中,R选自H、CH3、CH2CH3、CH(CH3)2、COCH3、COCH2CH3、COCH(CH3)2或COC(CH3)=CH2。
进一步地,所述的如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐,为如下任一种:
进一步地,成盐用的酸为氯化氢、溴化氢、硫酸、碳酸、草酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸或阿魏酸。
一种药物组合物,其中含有所述的如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐及药学上可接受的载体。
如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐在制备抗肿瘤药物中的用途。
一种如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐的制备方法,其特征在于:包括如下步骤:
(1)化合物1在催化剂和碳酸钾作用下,和4-(4-boc-1-哌嗪基)苯基硼酸频那醇酯在DMF中回流得到1-1;
(2)化合物1-1在三氟乙酸作用下脱去保护基得到1-2;
(3)化合物1-2在缩合剂HATU作用下与2-氟-5-((4-氧-3,4-二氢酞嗪-1-基)甲基)苯甲酸反应得到化合物1-3;
(4)化合物1-3在LIOH作用下水解甲酯得到1-4;
(5)化合物1-4在缩合剂HATU作用下与3-(氨甲基)-4,6-二甲基-1H-吡啶-2-酮反应得到I,
(1)化合物2在催化剂和碳酸钾作用下,和4-(4-boc-1-哌嗪基)苯基硼酸频那醇酯在DMF中回流得到2-1;
(2)化合物2-1在三氟乙酸作用下脱去保护基得到2-2;
(3)化合物2-2在缩合剂HATU作用下与2-氟-5-((4-氧-3,4-二氢酞嗪-1-基)甲基)苯甲酸反应得到化合物2-3;
(4)化合物2-3在LIOH作用下水解甲酯得到2-4;
(5)化合物2-4在缩合剂HATU作用下与3-(氨甲基)-4,6-二甲基-1H-吡啶-2-酮反应得到II。
以下是上述制备方法的优选方案:
在烧瓶中加入不同取代的2-甲基-3-氨基-5-溴苯甲酸甲酯1,4-(4-boc-1-哌嗪基)苯基硼酸频那醇酯,碳酸钾和[1,1′-双(二苯基膦基)二茂铁]二氯化钯,加入DMF溶解并在氮气保护下80℃反应2-4h,监测反应至完全,加入HCl溶液酸化,乙酸乙酯萃取,合并乙酸乙酯相,洗涤有机相,干燥,浓缩后用硅胶柱色谱分离,乙酸乙酯/石油醚体系洗脱得目标产物1-1;接下来将1-1溶于二氯甲烷中,加入三氟乙酸反应6h,调节PH后得到化合物1-2;将将化合物1-2和2-氟-5-((4-氧-3,4-二氢酞嗪-1-基)甲基)苯甲酸溶解于DCM中,加入DIPEA和HATU,反应2h后得到化合物1-3;然后将1-3溶解于甲醇/水中,加入LiOH反应12h,用1MHCl调节pH至中性,得到化合物1-4;最后,将1-4和3-(氨甲基)-4,6-二甲基-1H-吡啶-2-酮溶于DCM中,加入DIPEA和HATU。反应2h后,用色谱柱分离得到化合物I。
在烧瓶中加入不同取代的2-甲基-3-乙胺基-5-溴苯甲酸甲酯2,4-(4-boc-1-哌嗪基)苯基硼酸频那醇酯,碳酸钾和[1,1'-双(二苯基膦基)二茂铁]二氯化钯,加入DMF溶解并在氮气保护下80℃反应2-4h,监测反应至完全,加入HCl溶液酸化,乙酸乙酯萃取,合并乙酸乙酯相,洗涤有机相,干燥,浓缩后用硅胶柱色谱分离,乙酸乙酯/石油醚体系洗脱得目标产物2-1;接下来将2-1溶于二氯甲烷中,加入三氟乙酸反应6h,调节PH后得到化合物2-2;将将化合物2-2和2-氟-5-((4-氧-3,4-二氢酞嗪-1-基)甲基)苯甲酸溶解于DCM中,加入DIPEA和HATU,反应2h后得到化合物2-3;然后将2-3溶解于甲醇/水中,加入LiOH反应12h,用1MHCl调节pH至中性,得到化合物2-4;最后,将2-4和3-(氨甲基)-4,6-二甲基-1H-吡啶-2-酮溶于DCM中,加入DIPEA和HATU。反应2h后,用色谱柱分离得到化合物II。
有益效果:本发明的抑制剂对人乳腺癌细胞MDA-MB-231和MDA-MB-468和MCF-7抑制效果较好,对人正常乳腺细胞MCF-10A和人正常肝细胞L02毒性较小,并且保持了良好的对PARP-1和EZH2的体外抑制活性,有作为抗肿瘤药物的巨大潜力。本发明可作为肿瘤的单一治疗剂,或者与其它抗肿瘤药物联用,从而达到提高现有抗肿瘤药物疗效并降低剂量和毒性的作用。
具体实施方式
实例1
化合物(I-1):氮-((4,6-二甲基-2-氧-1,2-二氢吡啶-3)甲基)-3-(6-(4-(2-氟-5-((4-氧-3,4-酞嗪基-1)甲基)苯甲酰基)哌嗪-1-)吡啶-3)-3-氨基-2-甲基苯甲酰胺.产率52%.mp:192-194℃;1H NMR(500MHz,DMSO-d6)δ(ppm):12.61(s,1H),11.48(s,1H),8.33(d,J=2.5Hz,1H),8.27(d,J=7.5Hz,1H),8.02(t,J=2.5Hz,1H),7.99(m,1H),7.90(t,J=7.5Hz,1H),7.85(t,J=7.5Hz,1H),7.74(m,1H),7.46-7.39(m,2H),7.26(t,J=9.0Hz,1H),6.90(d,J=9.0Hz,1H),6.87(d,J=2.5Hz,1H),6.67(d,J=2.5Hz,1H,5.86(s,1H),5.04(s,2H),4.35(s,2H),4.26(d,J=7.5Hz,2H),3.75-3.73(m,2H),3.67-3.65(m,2H),3.52-3.49(m,2H),3.31-3.28(m,2H),2.20(s,3H),2.11(s,3H),2.02(s,3H);13C NMR(125MHz,DMSO-d6)δ(ppm):164.46,163.98,163.05,159.40,157.75,156.42(C,d,JC-F=202.5Hz),149.39,147.53,145.00,144.90,138.80,135.59,134.86(C,d,JC-C-C-C-F=2.5Hz),133.53,131.73(C,d,JC-C-C-F=7.5Hz),131.60,129.10,129.00(C,d,J C-C-C-F=2.5Hz),127.91,126.09,125.81,125.49,123.73(C,d,JC-C-F=15.0Hz),121.71,118.38,117.23,116.38,115.97(C,d,JC-C-F=15.0Hz),112.73,111.74,107.41,107.24,46.14,44.98,44.49,41.12,36.44,34.90,18.93,18.19,13.60;HRMS:[M+Na]+calcd for C41H39FN8NaO4749.2971,found749.2971.
实例2
化合物(I-2):氮-((4,6-二甲基-2-氧-1,2-二氢吡啶-3)甲基)-3-(6-(4-(2-氟-5-((4-氧-3,4-酞嗪基-1)甲基)苯甲酰基)哌嗪-1-)吡啶-3)-3-乙氨基-2-甲基苯甲酰胺.产率:53%.mp:192-194℃;1H NMR(500MHz,DMSO-d6)δ(ppm):12.61(s,1H),11.47(s,1H),8.42(d,J=2.5Hz,1H),8.27(t,J=5.0Hz,1H),8.04(t,J=5.0Hz,1H),7.98(d,J=5.0Hz,1H),7.91(t,J=7.5Hz,1H),7.86(t,J=7.5Hz,1H),7.61(s,1H),7.46-7.40(m,2H),7.26(t,J=9.0Hz,1H),6.90(d,J=9.0Hz,1H),6.68(d,J=9.0Hz,2H),5.86(s,1H),4.35(s,2H),4.27(d,J=2.5Hz,2H),3.75-3.73(m,2H),3.67-3.65(m,2H),3.52-3.49(m,2H),3.31-3.28(m,2H),2.80(d,J=5.0Hz,3H),2.69(s,1H),2.20(s,3H),2.10(s,3H),2.03(s,3H);13CNMR(125MHz,DMSO-d6)δ(ppm):169.51,163.98,163.03,159.40,157.74,156.42(C,d,JC-F=202.5Hz),149.39,147.24,145.23,144.91,142.67,138.63,135.90,135.13,134.86(C,d,JC-C-C-C-F=2.5Hz),133.54,131.73(C,d,JC-C-C-F=7.5Hz),131.62,129.10,129.00(C,d,JC-C-C-F=2.5Hz),127.91,126.21,126.10,125.50,123.73(C,d,JC-C-F=15.0Hz),121.69,117.89,115.97(C,d,JC-C-F=15.0Hz),112.19,107.38,107.25,107.00,48.61,46.13,45.02,44.55,41.11,36.45,34.92,18.94,18.03,16.73,13.66;HRMS:[M+Na]+calcd forC43H43FN8NaO4777.3284,found 777.3293.
实例3
化合物(I-3):氮-((4,6-二甲基-2-氧-1,2-二氢吡啶-3)甲基)-3-(6-(4-(2-氟-5-((4-氧-3,4-酞嗪基-1)甲基)苯甲酰基)哌嗪-1-)吡啶-3)-3-乙酰胺基-2-甲基苯甲酰胺.产率:50%.mp:220-222℃;1H NMR(500MHz,DMSO-d6)δ(ppm):12.61(s,1H),11.49(s,1H),9.44(s,1H),8.41(d,J=2.5Hz,1H),8.28(t,J=5.0Hz,1H),7.98(d,J=5.0Hz,1H),7.91(t,J=7.5Hz,1H),7.85(t,J=7.5Hz,2H),7.61(s,1H),7.46-7.40(m,2H),7.29(s,1H),7.25(t,J=9.0Hz,1H),6.92(d,J=9.0Hz,1H),5.87(s,1H),4.35(s,2H),4.31(d,J=2.5Hz,2H),3.75-3.73(m,2H),3.67-3.65(m,2H),3.52-3.49(m,2H),3.31-3.28(m,2H),2.20(s,3H),2.16(s,3H),2.11(s,3H),2.08(s,3H);13C NMR(125MHz,DMSO-d6)δ(ppm):168.59,168.44,163.99,163.02,159.42,157.92,156.42(C,d,JC-F=202.5Hz),149.58,145.30,144.92,142.78,138.94,137.51,135.78,134.86(C,d,JC-C-C-C-F=2.5Hz),134.43,133.55,131.73(C,d,JC-C-C-F=7.5Hz),131.62,129.11,129.00(C,d,JC-C-C-F=2.5Hz),128.27,127.91,126.11,125.51,124.65,123.73(C,d,JC-C-F=15.0Hz),123.41,121.56,121.49,115.97(C,d,JC-C-F=15.0Hz),107.39,107.28,46.14,44.90,44.42,41.12,36.45,34.97,23.27,18.96,18.21,14.41;HRMS:[M+Na]+calcd for C43H41FN8NaO5 768.3076,found 768.3079.
实例4
化合物(I-4):氮-((4,6-二甲基-2-氧-1,2-二氢吡啶-3)甲基)-3-(6-(4-(2-氟-5-((4-氧-3,4-酞嗪基-1)甲基)苯甲酰基)哌嗪-1-)吡啶-3)-3-丙酰胺基-2-甲基苯甲酰胺.产率:50%.mp:235-237℃;1H NMR(500MHz,DMSO-d6)δ(ppm):12.61(s,1H),11.49(s,1H),9.37(s,1H),8.42(d,J=2.5Hz,1H),8.28(m,2H),7.98(d,J=5.0Hz,1H),7.92(t,J=7.5Hz,1H),7.85(t,J=7.5Hz,2H),7.60(s,1H),7.46-7.40(m,2H),7.29(s,1H),7.25(t,J=9.0Hz,1H),6.94(d,J=9.0Hz,1H),5.87(s,1H),4.35(s,2H),4.30(d,J=2.5Hz,2H),3.75-3.73(m,2H),3.67-3.65(m,2H),3.52-3.49(m,2H),3.31-3.28(m,2H),2.37(q,J=6.5Hz,2H),2.21(s,3H),2.16(s,3H),2.11(s,3H),1.12(t,J=6.5Hz,3H);13C NMR(125MHz,DMSO-d6)δ(ppm):172.15,168.80,163.99,163.01,159.41,157.92,156.42(C,d,JC-F=202.5Hz),149.57,145.31,144.92,142.78,138.94,137.51,135.78,134.86(C,d,JC-C-C-C-F=2.5Hz),134.43,133.55,131.73(C,d,JC-C-C-F=7.5Hz),131.62,129.11,129.00(C,d,JC-C-C-F=2.5Hz),128.27,127.91,126.11,125.51,124.65,123.73(C,d,JC-C-F=15.0Hz),123.41,121.56,121.49,115.97(C,d,JC-C-F=15.0Hz),107.39,107.28,46.13,44.90,44.42,41.12,36.45,34.96,28.92,18.96,18.21,14.37,9.92;HRMS:[M+Na]+calcd forC44H43FN8NaO5805.3233,found 805.3236.
实例5
化合物(I-5):氮-((4,6-二甲基-2-氧-1,2-二氢吡啶-3)甲基)-3-(6-(4-(2-氟-5-((4-氧-3,4-酞嗪基-1)甲基)苯甲酰基)哌嗪-1-)吡啶-3)-3-异丁酰胺基-2-甲基苯甲酰胺.产率:46%.mp:270-272℃;1H NMR(500MHz,DMSO-d6)δ(ppm):12.61(s,1H),11.48(s,1H),9.34(s,1H),8.42(d,J=2.5Hz,1H),8.28(m,2H),7.98(d,J=5.0Hz,1H),7.92(t,J=7.5Hz,1H),7.85(t,J=7.5Hz,2H),7.54(s,1H),7.46-7.40(m,2H),7.30(s,1H),7.26(t,J=9.0Hz,1H),6.93(d,J=9.0Hz,1H),5.86(s,1H),4.35(s,2H),4.30(d,J=2.5Hz,2H),3.75-3.73(m,2H),3.67-3.65(m,2H),3.52-3.49(m,2H),3.31-3.28(m,2H),2.67(m,1H),2.20(s,3H),2.14(s,3H),2.11(s,3H),1.13(d,J=6.0Hz,6H);13C NMR(125MHz,DMSO-d6)δ(ppm):175.27,168.57,163.99,163.01,159.40,157.88,156.42(C,d,JC-F=202.5Hz),149.56,145.26,144.91,142.75,138.93,137.45,135.82,134.86(C,d,JC-C-C-C-F=2.5Hz),134.41,133.54,131.73(C,d,JC-C-C-F=7.5Hz),131.62,129.10,129.00(C,d,JC-C-C-F=2.5Hz),128.78,127.91,126.11,125.50,124.62,123.73(C,d,JC-C-F=15.0Hz),123.67,121.60,121.49,115.97(C,d,JC-C-F=15.0Hz),107.35,107.28,46.12,44.90,44.42,41.11,36.44,34.95,34.31,19.64,18.95,18.20,14.30;HRMS:[M+Na]+calcd forC45H45FN8Nao5819.3389,found 819.3400.
实例6
化合物(II-1):氮-((4,6-二甲基-2-氧-1,2-二氢吡啶-3)甲基)-3-(6-(4-(2-氟-5-((4-氧-3,4-酞嗪基-1)甲基)苯甲酰基)哌嗪-1-)吡啶-3)-3-乙酰胺基-2-甲基苯甲酰胺.产率:44%.mp:172-174℃;1H NMR(500MHz,DMSO-d6)δ(ppm):12.61(s,1H),11.48(s,1H),8.51(d,J=2.5Hz,1H),8.34(t,J=5.0Hz,1H),8.27(d,J=5.0Hz,1H),8.00(d,J=5.0Hz,1H),7.91(t,J=7.5Hz,1H),7.84(t,J=7.5Hz,1H),7.73(s,1H),7.50-7.39(m,4H),7.26(t,J=9.0Hz,1H),6.92(d,J=9.0Hz,1H),5.87(s,1H),4.35(s,2H),4.31(d,J=2.5Hz,2H),4.05(d,J=5.0Hz,2H),3.75-3.73(m,2H),3.67-3.65(m,2H),3.52-3.49(m,2H),3.09-3.00(m,2H),2.22(s,3H),2.14(s,3H),1.77(s,3H),1.68(s,3H),1.03(t,J=5.0Hz,3H);13C NMR(125MHz,DMSO-d6)δ(ppm):169.85,168.22,164.05,163.06,159.45,158.06,156.42(C,d,JC-F=202.5Hz),149.75,149.41,145.60,144.96,142.81,142.25,140.05,135.99,135.87134.88(C,d,JC-C-C-C-F=2.5Hz)133.59,131.73(C,d,JC-C-C-F=7.5Hz),131.66,131.33,129.12,129.00(C,d,JC-C-C-F=2.5Hz),127.92,126.84,126.13,125.54,124.01,123.73(C,d,JC-C-F=15.0Hz),122.03,121.48,115.97(C,d,JC-C-F=15.0Hz),107.41,107.28,46.15,44.90,44.41,42.24,41.15,36.47,34.98,22.42,18.87,18.22,14.05,12.74;HRMS:[M+Na]+calcd for C45H45FN8NaO5819.3389,found 819.3396.
实例7
化合物(II-2):氮-((4,6-二甲基-2-氧-1,2-二氢吡啶-3)甲基)-3-(6-(4-(2-氟-5-((4-氧-3,4-酞嗪基-1)甲基)苯甲酰基)哌嗪-1-)吡啶-3)-3-丙酰胺基-2-甲基苯甲酰胺.产率:43%.mp:280-282℃;1H NMR(500MHz,DMSO-d6)δ(ppm):12.59(s,1H),11.47(s,1H),8.50(d,J=2.5Hz,1H),8.33(t,J=5.0Hz,1H),8.27(d,J=5.0Hz,1H),8.00(m,2H),7.91(m,2H),7.50-7.39(m,4H),7.25(t,J=9.0Hz,1H),6.92(d,J=9.0Hz,1H),5.86(s,1H),4.34(s,2H),4.29(d,J=2.5Hz,2H),3.75-3.73(m,2H),3.67-3.65(m,2H),3.52-3.49(m,2H),3.09-3.00(m,2H),2.22(s,3H),2.89(s,3H),2.73(s,3H),2.21(s,3H),2.11(m,4H),1.03(t,J=5.0Hz,3H),0.90(t,J=5.0Hz,3H);13C NMR(125MHz,DMSO-d6)δ(ppm):171.98,168.19,164.02,163.01,162.35,159.42,158.05,156.42(C,d,JC-F=202.5Hz),149.68,145.59,144.92,142.87,141.79,140.07,135.95,135.84,134.86(C,d,JC-C-C-C-F=2.5Hz),133.55,131.73(C,d,JC-C-C-F=7.5Hz),131.63,131.41,129.11,129.00(C,d,JC-C-C-F=2.5Hz),127.92,126.94,126.11,125.51,123.98,123.79,123.73(C,d,JC-C-F=15.0Hz),121.49,115.97(C,d,JC-C-F=15.0Hz),107.39,107.23,46.15,44.90,44.41,42.24,41.15,36.47,34.98,22.42,18.87,18.22,14.05,12.74;HRMS:[M+Na]+calcd forC46H47FN8NaO5833.3546,found 833.3550.
实例8
化合物(II-3):氮-((4,6-二甲基-2-氧-1,2-二氢吡啶-3)甲基)-3-(6-(4-(2-氟-5-((4-氧-3,4-酞嗪基-1)甲基)苯甲酰基)哌嗪-1-)吡啶-3)-3-甲基丙烯基-2-甲基苯甲酰胺.产率:40%.mp:204-206℃;1H NMR(500MHz,DMSO-d6)δ(ppm):12.62(s,1H),11.50(s,1H),8.46(d,J=2.5Hz,1H),8.33(t,J=5.0Hz,1H),8.26(d,J=5.0Hz,1H),8.00(m,1H),7.91(m,3H),7.50-7.39(m,4H),7.25(t,J=9.0Hz,1H),6.92(d,J=9.0Hz,1H),5.87(s,1H),4.96(s,1H),4.86(s,1H),4.35(s,2H),4.29(d,J=2.5Hz,2H),3.75-3.73(m,2H),3.67-3.65(m,2H),3.52-3.49(m,2H),3.09-3.00(m,2H),2.21(s,3H),2.17(s,3H),2.11(s,3H),1.69(s,3H);13C NMR(125MHz,DMSO-d6)δ(ppm):170.35,168.19,164.02,163.01,162.35,159.41,158.05,156.42(C,d,JC-F=202.5Hz),149.68,145.59,144.91,142.87,142.22,141.79,140.07,135.95,135.84,134.86(C,d,JC-C-C-C-F=2.5Hz),133.55,131.73(C,d,JC-C-C-F=7.5Hz),131.63,131.41,129.11,129.00(C,d,JC-C-C-F=2.5Hz),127.91,126.94,126.10,125.52,123.98,123.79,123.73(C,d,JC-C-F=15.0Hz),121.49,115.97(C,d,JC-C-F=15.0Hz),107.39,107.23,46.15,44.87,44.36,41.11,36.44,34.97,20.13,18.97,18.20,12.16;HRMS:[M+Na]+calcd for C47H47FN8NaO5845.3546,found 845.3548.
实施例9
本发明部分化合物的药理学实验及结果如下:
一、PARP-1,EZH2抑制活性;MDA-MB-231和MDA-MB-468细胞抑制活性:
实验方法:测定化合物在10nM时对PARP-1抑制活性,采用HT通用化学发光PARP检测试剂盒检测,Olaparib作为阳性对照;测定化合物1-5在50nM时对EZH2抑制活性,采用组蛋白甲基转移酶活性/抑制测定试剂盒检测,Tazemetostat作为阳性对照;MDA-MB-231和MDA-MB-468细胞抑制活性采用MTT法得到IC50。按照每个化合物设置三个副孔,每个实验重复三次,实验结果表达为平均值±SEM。
表1本发明化合物在10nM对PARP-1抑制率和在50nM对EZH2抑制率;本发明化合对MDA-MB-231和MDA-MB-468细胞抑制活性
a用三个独立实验的剂量响应曲线的平均SD表示;b处理72h后采用MTT法检测细胞活力;c化合物在10nM处的抑制率;d化合物在50nM处的抑制率。
从表1可知,化合物i-3对两种细胞的抑制活性和对两种酶的抑制活性较好,接下来我们测定I-3对两种酶的半数抑制率,以及对人正常乳腺细胞MCF-10A,人正常肝细胞L02,人乳腺癌细胞MCF-7抑制率。
表2化合物I-3对几种细胞的抑制活性,以及对PARP-1和EZH2的抑制活性
a用三个独立实验的剂量响应曲线的平均SD表示;b未检测到。
表2表明化合物I-3对人正常细胞毒性较小,对几种肿瘤细胞抑制作用较好,并且保持了良好的对PARP-1和EZH2的体外抑制活性,有作为抗肿瘤药物的潜力。
Claims (6)
3.根据权利要求1如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐,其特征在于:成盐用的酸为氯化氢、溴化氢、硫酸、碳酸、草酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸或阿魏酸。
4.一种药物组合物,其中含有权利要求1~3中任一项所述的如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐及药学上可接受的载体。
5.如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐在制备抗肿瘤药物中的用途。
6.一种如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐的制备方法,其特征在于:包括如下步骤:
(1)化合物1在催化剂和碳酸钾作用下,和4-(4-boc-1-哌嗪基)苯基硼酸频那醇酯在DMF中回流得到1-1;
(2)化合物1-1在三氟乙酸作用下脱去保护基得到1-2;
(3)化合物1-2在缩合剂HATU作用下与2-氟-5-((4-氧-3,4-二氢酞嗪-1-基)甲基)苯甲酸反应得到化合物1-3;
(4)化合物1-3在LIOH作用下水解甲酯得到1-4;
(5)化合物1-4在缩合剂HATU作用下与3-(氨甲基)-4,6-二甲基-1H-吡啶-2-酮反应得到I,
(1)化合物2在催化剂和碳酸钾作用下,和4-(4-boc-1-哌嗪基)苯基硼酸频那醇酯在DMF中回流得到2-1;
(2)化合物2-1在三氟乙酸作用下脱去保护基得到2-2;
(3)化合物2-2在缩合剂HATU作用下与2-氟-5-((4-氧-3,4-二氢酞嗪-1-基)甲基)苯甲酸反应得到化合物2-3;
(4)化合物2-3在LIOH作用下水解甲酯得到2-4;
(5)化合物2-4在缩合剂HATU作用下与3-(氨甲基)-4,6-二甲基-1H-吡啶-2-酮反应得到II。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110337356.4A CN113024516B (zh) | 2021-03-29 | 2021-03-29 | 双靶点parp/ezh2抑制剂、制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110337356.4A CN113024516B (zh) | 2021-03-29 | 2021-03-29 | 双靶点parp/ezh2抑制剂、制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113024516A true CN113024516A (zh) | 2021-06-25 |
CN113024516B CN113024516B (zh) | 2022-05-17 |
Family
ID=76452687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110337356.4A Active CN113024516B (zh) | 2021-03-29 | 2021-03-29 | 双靶点parp/ezh2抑制剂、制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113024516B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080976A1 (en) * | 2003-03-12 | 2004-09-23 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
CN102107008A (zh) * | 2003-12-01 | 2011-06-29 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
CN102898378A (zh) * | 2012-11-16 | 2013-01-30 | 江苏先声药业有限公司 | 一类酞嗪酮衍生物及其应用 |
CN104540500A (zh) * | 2012-03-12 | 2015-04-22 | Epizyme股份有限公司 | 人ezh2抑制剂及其应用方法 |
CN104768555A (zh) * | 2012-04-13 | 2015-07-08 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
US20180207144A1 (en) * | 2012-05-16 | 2018-07-26 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
CN108358850A (zh) * | 2018-02-11 | 2018-08-03 | 中国药科大学 | PARP-1和Tankyrase1/2多靶点抑制剂、其制法及用途 |
CN109810098A (zh) * | 2017-11-21 | 2019-05-28 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp-1和pi3k双靶点抑制剂 |
CN110054615A (zh) * | 2018-01-19 | 2019-07-26 | 南京圣和药业股份有限公司 | 三嗪类idh抑制剂甲磺酸盐的晶型 |
CN111592487A (zh) * | 2020-06-09 | 2020-08-28 | 新乡医学院 | 一类含羟肟酸基团的二芳基乙烯类LSD1/HDACs双靶点抑制剂、其制备方法及应用 |
-
2021
- 2021-03-29 CN CN202110337356.4A patent/CN113024516B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080976A1 (en) * | 2003-03-12 | 2004-09-23 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
CN102107008A (zh) * | 2003-12-01 | 2011-06-29 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
CN104540500A (zh) * | 2012-03-12 | 2015-04-22 | Epizyme股份有限公司 | 人ezh2抑制剂及其应用方法 |
CN104768555A (zh) * | 2012-04-13 | 2015-07-08 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
US20180207144A1 (en) * | 2012-05-16 | 2018-07-26 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
CN102898378A (zh) * | 2012-11-16 | 2013-01-30 | 江苏先声药业有限公司 | 一类酞嗪酮衍生物及其应用 |
CN109810098A (zh) * | 2017-11-21 | 2019-05-28 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp-1和pi3k双靶点抑制剂 |
CN110054615A (zh) * | 2018-01-19 | 2019-07-26 | 南京圣和药业股份有限公司 | 三嗪类idh抑制剂甲磺酸盐的晶型 |
CN108358850A (zh) * | 2018-02-11 | 2018-08-03 | 中国药科大学 | PARP-1和Tankyrase1/2多靶点抑制剂、其制法及用途 |
CN111592487A (zh) * | 2020-06-09 | 2020-08-28 | 新乡医学院 | 一类含羟肟酸基团的二芳基乙烯类LSD1/HDACs双靶点抑制剂、其制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113024516B (zh) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021129820A1 (zh) | 含螺环的喹唑啉化合物 | |
WO2021190467A1 (zh) | 含螺环的喹唑啉化合物 | |
WO2021129824A1 (zh) | 新型K-Ras G12C抑制剂 | |
WO2020259432A1 (zh) | Kras-g12c抑制剂 | |
EP4144732A1 (en) | Benzothiazolyl biaryl compound, and preparation method and use | |
CN104926793B (zh) | 一种治疗肿瘤的化合物及其用途 | |
JPH10101591A (ja) | ウイルス感染症の予防・治療剤 | |
WO2013178021A1 (zh) | 吡咯并[2,1—f][1,2,4]三嗪衍生物及其抗肿瘤用途 | |
WO2001079184A1 (fr) | Composes de piperazine substitues | |
CN111440161B (zh) | 一种具有par4拮抗活性的二环杂芳基类化合物及其应用 | |
WO2022063297A1 (zh) | 喹唑啉衍生物及其制备方法和用途 | |
CN114957248B (zh) | 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用 | |
CA3054459A1 (en) | Azetidine derivative | |
CN113045570A (zh) | 含螺环的喹唑啉化合物 | |
CN111116469A (zh) | 一种hdac抑制剂、制备方法、药物组合物及其用途 | |
CN113024516B (zh) | 双靶点parp/ezh2抑制剂、制备方法及用途 | |
CN115368306B (zh) | 含四氢异喹啉类结构的hdac抑制剂、组合物及其用途 | |
CN115819418A (zh) | Plk1激酶抑制剂及其制备方法和应用 | |
CN113717174B (zh) | 肿瘤靶向性抗耐药o6-噻吩甲基鸟嘌呤-吲哚醌-氯乙基亚硝基脲联合分子及其制备方法 | |
CN109651377B (zh) | 一种治疗癌症的化合物及其用途 | |
CN111303163B (zh) | 具有jak激酶抑制活性化合物、制备方法、组合物及用途 | |
Li et al. | Synthesis and biological activities of dibenzyl dipiperazine diquaternary ammonium salts | |
CN107522659B (zh) | 3-硝基喹啉类衍生物及其制备方法和应用 | |
CN111247143B (zh) | 可用作蛋白激酶抑制剂的吡啶并喹唑啉衍生物 | |
CN113754659A (zh) | 含螺环的喹唑啉化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |